Treatment Options for Anemia, Taking Risks Into Consideration: Erythropoiesis-Stimulating Agents Versus Transfusions

Oncologist- United States

doi 10.1634/theoncologist.13-s3-27

Full Text

Abstract

Available in

Date

May 1, 2008

Authors

Jean‐Philippe Spano

David Khayat

Publisher

Alphamed Press

Related search

Anemia Treatment With Q2W Darbepoetin Alfa in Patients With Chronic Kidney Disease Naïve to Erythropoiesis-Stimulating Agents

Current Medical Research and Opinion

Medicine

2008

English

PCN34 Cost Analysis of Anemia Treatment With Erythropoiesis-Stimulating Agents (ESAs) in Cancer Patients Receiving Chemotherapy in Italy

English

Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update

Journal of Oncology Practice

Health Policy

Oncology

2019

English

Managing Chemotherapy Induced Anemia With Darbepoetin Alfa and Other Erythropoiesis Stimulating Agents: A Nurse's Perspective

Nursing: Research and Reviews

2013

English

On Stimulating Curiosity and Taking Intellectual Risks

Human Resource Development Review

Human Resource Management

Organizational Behavior

2011

English

Effects of Anemia Correction by Erythropoiesis-Stimulating Agents on Cardiovascular Function in Non-Dialysis Patients With Chronic Kidney Disease

International Heart Journal

Medicine

Cardiovascular Medicine

Cardiology

2012

English

DGI-043 Increased Cost of Erythropoiesis-Stimulating Agents in Some Special Situations

European Journal of Hospital Pharmacy: Science and Practice

Pharmacy

2013

English

Association Between High-Dose Erythropoiesis-Stimulating Agents, Inflammatory Biomarkers, and Soluble Erythropoietin Receptors

BMC Nephrology

Nephrology

2011

English

Intravenous Iron Versus Oral Iron Versus No Iron With or Without Erythropoiesis- Stimulating Agents (ESA) for Cancer Patients With Anaemia: A Systematic Review and Network Meta-Analysis

Cochrane Database of Systematic Reviews

2017

English

Amanote Research

Treatment Options for Anemia, Taking Risks Into Consideration: Erythropoiesis-Stimulating Agents Versus Transfusions

Oncologist- United States

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Anemia Treatment With Q2W Darbepoetin Alfa in Patients With Chronic Kidney Disease Naïve to Erythropoiesis-Stimulating Agents

PCN34 Cost Analysis of Anemia Treatment With Erythropoiesis-Stimulating Agents (ESAs) in Cancer Patients Receiving Chemotherapy in Italy

Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update

Managing Chemotherapy Induced Anemia With Darbepoetin Alfa and Other Erythropoiesis Stimulating Agents: A Nurse's Perspective

On Stimulating Curiosity and Taking Intellectual Risks

Effects of Anemia Correction by Erythropoiesis-Stimulating Agents on Cardiovascular Function in Non-Dialysis Patients With Chronic Kidney Disease

DGI-043 Increased Cost of Erythropoiesis-Stimulating Agents in Some Special Situations

Association Between High-Dose Erythropoiesis-Stimulating Agents, Inflammatory Biomarkers, and Soluble Erythropoietin Receptors

Intravenous Iron Versus Oral Iron Versus No Iron With or Without Erythropoiesis- Stimulating Agents (ESA) for Cancer Patients With Anaemia: A Systematic Review and Network Meta-Analysis

Amanote Research

Treatment Options for Anemia, Taking Risks Into Consideration: Erythropoiesis-Stimulating Agents Versus Transfusions

Oncologist- United States

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Anemia Treatment With Q2W Darbepoetin Alfa in Patients With Chronic Kidney Disease Naïve to Erythropoiesis-Stimulating Agents

PCN34 Cost Analysis of Anemia Treatment With Erythropoiesis-Stimulating Agents (ESAs) in Cancer Patients Receiving Chemotherapy in Italy

Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update

Managing Chemotherapy Induced Anemia With Darbepoetin Alfa and Other Erythropoiesis Stimulating Agents: A Nurse&#39;s Perspective

On Stimulating Curiosity and Taking Intellectual Risks

Effects of Anemia Correction by Erythropoiesis-Stimulating Agents on Cardiovascular Function in Non-Dialysis Patients With Chronic Kidney Disease

DGI-043 Increased Cost of Erythropoiesis-Stimulating Agents in Some Special Situations

Association Between High-Dose Erythropoiesis-Stimulating Agents, Inflammatory Biomarkers, and Soluble Erythropoietin Receptors

Intravenous Iron Versus Oral Iron Versus No Iron With or Without Erythropoiesis- Stimulating Agents (ESA) for Cancer Patients With Anaemia: A Systematic Review and Network Meta-Analysis

Managing Chemotherapy Induced Anemia With Darbepoetin Alfa and Other Erythropoiesis Stimulating Agents: A Nurse's Perspective